Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic prostate cancer because of both benign prostate tissue and malignant prostate tissue express androgen receptor (AR), which prostate cancer cells require for their growth and cancer progression [4, 5]. Here, AR is linked to prostate carcinoma.